Sunday, October 24, 2021
HomeHealthBiogen's debated Alzheimer's drug given to first patient

Biogen’s debated Alzheimer’s drug given to first patient

A Rhode Island man became the first patient worldwide to receive Biogen’s hotly debated Alzheimer’s drug outside of a clinical trial on Wednesday, a hospital spokesperson confirmed to Fox News.Marc Archambault, 70 of Wakefield, received the infusion shortly before noon at Butler Hospital in Providence, according to spokesperson Raina Smith of Care New England. The patient met the criteria for people diagnosed with mild cognitive impairment or early Alzheimer’s disease, Smith said.WHO SHOULD TAKE NEW ALZHEIMER’S DRUG? EXPERT WEIGHS IN
Dr. Stephen Salloway, director of the memory and aging program at Butler Hospital, patient Marc Archambault, and Marc’s friend Karen Poole. (Photo courtesy of Care New England Health System and Butler Hospital)
“It’s transforming how we treat Alzheimer’s,” Dr. Stephen Salloway, director of the memory and aging program at Butler Hospital, said at a press conference. “For those of you who don’t know, it’s a devastating disease. “The Food and Drug Administration last week approved Biogen’s Alzheimer’s drug albeit to mixed reviews. It is the first drug approved for Alzheimer’s in nearly 20 years. Part of the controversy in the medical community surrounding the drug’s approval stems from data collected during two Phase 3 clinical trials. One study met the primary endpoint and showed a reduction in clinical decline, while the other did not. In November 2020, the Peripheral and Central Nervous System Drugs Advisory Committee had said it was not reasonable to consider clinical benefit of the drug based on one successful study. Dr. Douglas Scharre, a neurologist and director of the division of Cognitive Neurology at Ohio State Wexner Medical Center and clinical investigator on Biogen’s studies, previously told Fox News that the antibody treatment works by clearing toxic amyloid proteins from brain tissue, though patients with late-stage Alzheimer’s disease are unlikely to benefit.FDA OK’S BIOGEN’S ALZHEIMER’S DRUG: WHAT IS ACCELERATED APPROVAL?”If the person is too far along in their disease, it’s not going to work, we don’t want to waste important health care dollars,” Scharre told Fox News at the time. If a patient starts treatment early, studies suggested a 23% slow in decline.This is a developing story, please check back for updates.Fox News’ Alexandria Hein contributed to this report.

image 100365595 14413751



Please enter your comment!
Please enter your name here

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Most Popular

Recent Comments